Wikidata entity: Q417942
C₂₄H₂₆FNO₄ (P274)
Quantities
| P4250 | defined daily dose | 60 |
| P2067 | mass | 411.185 |
| P233 | canonical SMILES | String | CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F | ??? |
| P373 | Commons category | String | Fluvastatin | ??? |
| P366 | has use | ... | Q12140 (medication) | medication |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P2017 | isomeric SMILES | String | CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C3=CC=C(C=C3)F | ??? |
| P8026 | LiverTox likelihood score | ... | Q83284157 (LiverTox toxicity likelihood category B) | LiverTox toxicity likelihood category B |
| P2175 | medical condition treated | ... | Q184559 (arteriosclerosis) | arteriosclerosis |
| P2175 | medical condition treated | ... | Q844935 (coronary artery disease) | coronary artery disease |
| P2175 | medical condition treated | ... | Q762713 (hypercholesterolemia) | hypercholesterolemia |
| P2175 | medical condition treated | ... | Q1467339 (hypertriglyceridemia) | hypertriglyceridemia |
| P2175 | medical condition treated | ... | Q1476525 (lipid metabolism disorder) | lipid metabolism disorder |
| P2175 | medical condition treated | ... | Q1827605 (lipedema) | lipedema |
| P2175 | medical condition treated | ... | Q12252367 (atherosclerosis) | atherosclerosis |
| P2175 | medical condition treated | ... | Q18554145 (familial hyperlipidemia) | familial hyperlipidemia |
| P129 | physically interacts with | ... | Q415607 (3-hydroxy-3-methylglutaryl-CoA reductase) | 3-hydroxy-3-methylglutaryl-CoA reductase |
| P3489 | pregnancy category | ... | Q3679274 (Australian pregnancy category D) | Australian pregnancy category D |
| P3489 | pregnancy category | ... | Q28123619 (US pregnancy category X) | US pregnancy category X |
| P769 | significant drug interaction | ... | Q326224 ((S)-(−)-colchicine) | (S)-(−)-colchicine |
| P769 | significant drug interaction | ... | Q367700 (cyclosporine) | cyclosporine |
| P769 | significant drug interaction | ... | Q384295 (gemfibrozil) | gemfibrozil |
| P769 | significant drug interaction | ... | Q418747 ((2R)-daptomycin) | (2R)-daptomycin |
| P769 | significant drug interaction | ... | Q419724 (fenofibrate) | fenofibrate |
| P769 | significant drug interaction | ... | Q577387 (bezafibrate) | bezafibrate |
| P769 | significant drug interaction | ... | Q3496452 (ciprofibrate) | ciprofibrate |
| P769 | significant drug interaction | ... | Q113368879 (rac-warfarin) | rac-warfarin |
| P3364 | stereoisomer of | ... | Q27117903 (fluvastatin sodium anti-isomer free acid) | fluvastatin sodium anti-isomer free acid |
| P3364 | stereoisomer of | ... | Q27117904 ((3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid) | (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid |
| P3364 | stereoisomer of | ... | Q27164881 ((3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-yl-2-indolyl]-3,5-dihydroxy-6-heptenoic acid) | (3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-yl-2-indolyl]-3,5-dihydroxy-6-heptenoic acid |
| P3364 | stereoisomer of | ... | Q27166430 ((3S,5R)-7-[3-(4-fluorophenyl)-1-propan-2-yl-2-indolyl]-3,5-dihydroxy-6-heptenoic acid) | (3S,5R)-7-[3-(4-fluorophenyl)-1-propan-2-yl-2-indolyl]-3,5-dihydroxy-6-heptenoic acid |
| P3364 | stereoisomer of | ... | Q106039178 ((3S,5R)-fluvastatin) | (3S,5R)-fluvastatin |
| P279 | subclass of | ... | Q134856 (carboxylic acid) | carboxylic acid |
| P279 | subclass of | ... | Q954845 (statin) | statin |
| P279 | subclass of | ... | Q106039176 (rac-(±)-fluvastatin) | rac-(±)-fluvastatin |
| P2868 | subject has role | ... | Q954845 (statin) | statin |
| P2868 | subject has role | ... | Q50429847 (anticholesteremic agents) | anticholesteremic agents |
| P2275 | World Health Organisation international non-proprietary name | Monolingualtext | fluvastatin | ??? |
Why not click here or view trends?
log id: 4595841